Experimental Alzheimer’s Drug Trial for High-Risk Individuals
Individuals who show no signs of memory loss will have the opportunity to participate in a clinical trial for a new Alzheimer’s drug that might prevent the onset of dementia before symptoms become apparent.
This study is specifically targeting healthy middle-aged participants recognized as having an increased risk of developing Alzheimer’s, and it’s being conducted by a trust within the NHS, contributing to a larger, international effort to tackle dementia.
The first participants in Europe will start their screening process on Monday. This recruitment effort aims to involve around 1,600 individuals aged between 55 and 80 from diverse locations globally, facilitated by the Surrey and Borders Partnership NHS foundation trust.
Potential participants from across the UK will undergo tests to ensure they have no memory issues, followed by a blood test to check for p-tau217, a biomarker associated with cognitive decline and Alzheimer’s development.
Past studies have indicated that individuals with the highest levels of this biomarker had a nearly 78% chance of experiencing cognitive impairment within a decade.
Moreover, research also suggests that blood tests measuring p-tau217 can accurately identify Alzheimer’s disease up to 95% of the time.
The PrevenTRON study, classified as a phase III trial, aims to determine whether administering a novel drug, Trontinemab, to eligible participants with elevated p-tau217 levels can effectively prevent dementia from developing initially.
Developed by the Swiss company Roche, Trontinemab targets amyloid plaques—harmful proteins that accumulate in the brain, potentially slowing and ultimately harming brain cells.
Early findings have shown promising results for Trontinemab, with studies reporting that it eliminates amyloid plaques in 90% of individuals with early-stage Alzheimer’s or mild cognitive issues within a 28-week timeframe, effectively removing one major aspect of the disease.
Prof. Ramin Nilforooshan, who is leading the PrevenTRON trial, remarked that this study symbolizes a shift in research from treating Alzheimer’s symptoms to focusing on prevention. “For a long time, the focus has been on addressing Alzheimer’s after symptoms are evident. PrevenTRON is about whether we can intervene earlier, before symptoms arise,” he explained.
He highlighted that studies like PrevenTRON hold the potential to benefit millions impacted by Alzheimer’s. Yet, he also pointed out the experimental nature of this treatment during an interview.
He stated, “I’m not saying this trial is magic. It’s an investigational medicine. We need to wait and see: will it work or not?”
By the end of the year, at least 15 hospitals and clinics across the UK are anticipated to join this study, with recruitment efforts led by the Surrey and Borders Partnership Trust.
The trial is projected to last between four to six years, during which participants will be randomly assigned to either receive Trontinemab or a placebo, while monitoring their progression towards any signs of dementia.
It’s notable that Alzheimer’s disease is believed to begin developing in the brain up to a decade before individuals typically seek help for memory-related issues.
The condition impacts approximately one in 14 people over 65, and around one in six over the age of 80.
For those interested in screening for the trial, they can reach out to the Surrey and Borders Partnership research team at 01372 216584 or via email.
